A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

January 22, 2007

Primary Completion Date

April 19, 2010

Study Completion Date

April 19, 2010

Conditions
Retinitis Pigmentosa
Interventions
DRUG

NT-501

Low Dose

DRUG

NT-501

High Dose

Trial Locations (12)

10016

NY University Medical Center, New York

33101

Bascom Palmer Eye Insitute, Miami

38163

The Hamilton Eye Institute, Memphis

48105

Kellogg Eye Center, Ann Arbor

75231

Retina Foundation of Southwest, Dallas

84112

University of Utah, Salt Lake City

84132

The University of Utah - John A. Moran Eye Center, Salt Lake City

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

95817

University of Califoria, Davis, Sacramento

94143-0730

University of California, San Francisco, San Francisco

55455-0501

University of Minnesota, Minneapolis

97239-4197

Casey Eye Institue, Portland

Sponsors
All Listed Sponsors
lead

Neurotech Pharmaceuticals

INDUSTRY

NCT00447980 - A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter